Selinexor in combination with R-CHOP for frontline treatment of non-Hodgkin lymphoma: results of a phase 1 study

Lignende værker

• Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model
  af: Muqbil, Irfana, et al.
  Udgivet: (2019)
• Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone
  af: Muqbil, Irfana, et al.
  Udgivet: (2016)
• Snail Nuclear Transport: the Gateways Regulating Epithelial-to-Mesenchymal Transition?
  af: Muqbil, Irfana, et al.
  Udgivet: (2014)
• Preclinical assessment with clinical validation of Selinexor with gemcitabine and nab-paclitaxel for the treatment of pancreatic ductal adenocarcinoma
  af: Azmi, Asfar S., et al.
  Udgivet: (2019)
• Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death
  af: Kashyap, Trinayan, et al.
  Udgivet: (2016)